Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COO
COO logo

COO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
69.810
Open
69.355
VWAP
69.27
Vol
174.88K
Mkt Cap
13.55B
Low
69.000
Amount
12.11M
EV/EBITDA(TTM)
14.54
Total Shares
195.11M
EV
15.93B
EV/OCF(TTM)
18.38
P/S(TTM)
3.33
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
Show More

Events Timeline

(ET)
2026-03-05
16:20:00
Sees FY26 Revenue of $4.306B-$4.346B
select
2026-03-05
16:20:00
Company Reports Q1 Revenue of $1.024B, Exceeding Expectations
select

News

PRnewswire
8.5
04-09PRnewswire
CooperVision Launches Sustainability Platform to Enhance Eco-Friendly Practices
  • Sustainability Commitment: CooperVision's launch of the MADE BETTER™ Promise aims to reduce the carbon footprint of its MyDay® daily disposable contact lenses through smarter choices and sustainable manufacturing processes, enhancing brand image and meeting eco-conscious consumer demands.
  • Plastic Neutrality Program: The company has partnered with Plastic Bank to successfully recycle over 659 million plastic bottles, demonstrating its proactive contribution to reducing ocean plastic pollution while creating economic benefits for communities in participating countries.
  • Innovative Material Use: The MADE BETTER™ Innovation program incorporates ISCC PLUS-certified lower-carbon plastics and aluminum, which reduces packaging carbon emissions for MyDay® products, thereby enhancing their market competitiveness.
  • Production Efficiency Improvement: At its Puerto Rico manufacturing facility, the implementation of combined heat and power technology has reduced greenhouse gas emissions per lens by approximately 30% compared to 2021, not only improving production efficiency but also aligning with global environmental trends.
Globenewswire
5.0
04-08Globenewswire
Telix Pharmaceuticals Appoints New Non-Executive Directors
  • Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
  • Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
  • Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
  • Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
Newsfilter
5.0
04-08Newsfilter
Telix Pharmaceuticals Appoints New Non-Executive Directors
  • Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
  • Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
  • William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
  • Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
moomoo
5.0
04-08moomoo
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
  • New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.

  • Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.

Barron's
4.5
03-24Barron's
S&P 500 Futures Drop in Pre-Market Trading; Piper Sandler and Intercorp Financial Services at the Forefront
  • Market Opening: U.S. stock markets are set to open in two hours.

  • Piper Sandler Performance: Piper Sandler Cos. (PIPR) saw an 11.0% increase in pre-market trading.

  • Intercorp Financial Services Performance: Intercorp Financial Services Inc. (IFS) experienced a 9.2% rise in pre-market trading.

  • Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.

CNBC
6.5
03-20CNBC
Value Investors Pitch Stock Ideas at New York Conference
  • CF Industries Cash Flow Advantage: Amid soaring liquid fertilizer prices due to shipping bottlenecks in the Strait of Hormuz, Jennifer Wallace from Summit Street Capital highlighted CF Industries as a structurally advantaged 'cash-flow machine,' benefiting from its exposure to globally priced fertilizers and low-cost U.S. natural gas, positioning it as one of the most profitable producers worldwide.
  • Signet Jewelers Steady Cash Flow: Wallace also pointed out that Signet Jewelers is undervalued by the market, as the company generates most of its sales in North America and holds a leading share in the U.S. bridal jewelry market, which supports steady cash generation despite concerns around consumer spending.
  • Investment Opportunities in Sports Stocks: Mario Gabelli of GAMCO Investors emphasized the scarcity of sports-related stocks tied to premium live content, identifying the Atlanta Braves, Madison Square Garden Sports, and Manchester United as attractive investments, particularly noting that Madison Square Garden Sports could see a 50% increase in value.
  • Scotts Miracle-Gro Undervalued: John Rogers from Ariel Investments highlighted Scotts Miracle-Gro's strong brand and potential for shareholder returns, expecting the lawn-care company to rely more on share buybacks, which he believes could drive both earnings and stock price higher.
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
Wall Street analysts forecast COO stock price to rise
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
73.00
Averages
90.33
High
100.00
Current: 0.000
sliders
Low
73.00
Averages
90.33
High
100.00
Citi
Neutral
downgrade
$87 -> $80
AI Analysis
2026-04-07
Reason
Citi
Price Target
$87 -> $80
AI Analysis
2026-04-07
downgrade
Neutral
Reason
Citi lowered the firm's price target on Cooper Companies to $80 from $87 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The "walls of worry are high" into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm's top picks are now Edwards Lifesciences and Intuitive Surgical.
Needham
Buy
maintain
$99 -> $101
2026-03-06
Reason
Needham
Price Target
$99 -> $101
2026-03-06
maintain
Buy
Reason
Needham raised the firm's price target on Cooper Companies to $101 from $99 and keeps a Buy rating on the shares. The company's Q1 results marked a solid start to the year, with end markets improving, the analyst tells investors in a research note. Cooper Companies is seeing solid operating efficiencies, which have helped drive margin expansion and earnings upside, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cooper Companies Inc (COO.O) is 15.58, compared to its 5-year average forward P/E of 24.45. For a more detailed relative valuation and DCF analysis to assess Cooper Companies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.45
Current PE
15.58
Overvalued PE
28.99
Undervalued PE
19.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
18.16
Current EV/EBITDA
12.10
Overvalued EV/EBITDA
21.23
Undervalued EV/EBITDA
15.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.77
Current PS
3.01
Overvalued PS
5.80
Undervalued PS
3.73

Financials

AI Analysis
Annual
Quarterly

Whales Holding COO

C
Concentric Capital Strategies, L.P.
Holding
COO
+9.35%
3M Return
H
Heartland Advisors, Inc.
Holding
COO
+6.03%
3M Return
K
Kovitz Investment Group Partners, LLC
Holding
COO
+5.89%
3M Return
T
The London Company of Virginia, LLC
Holding
COO
+5.84%
3M Return
C
Cramer Rosenthal McGlynn LLC
Holding
COO
+4.51%
3M Return
D
Diamond Hill Capital Management, Inc.
Holding
COO
+4.36%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cooper Companies Inc (COO) stock price today?

The current price of COO is 69 USD — it has decreased -0.66

What is Cooper Companies Inc (COO)'s business?

The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.

What is the price predicton of COO Stock?

Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cooper Companies Inc (COO)'s revenue for the last quarter?

Cooper Companies Inc revenue for the last quarter amounts to 1.02B USD, increased 6.16

What is Cooper Companies Inc (COO)'s earnings per share (EPS) for the last quarter?

Cooper Companies Inc. EPS for the last quarter amounts to 0.66 USD, increased 26.92

How many employees does Cooper Companies Inc (COO). have?

Cooper Companies Inc (COO) has 15000 emplpoyees as of April 21 2026.

What is Cooper Companies Inc (COO) market cap?

Today COO has the market capitalization of 13.55B USD.